UCB Pharma Limited

208 Bath Road, Slough, Berkshire, SL1 3WE
Telephone: +44 (0)1753 534 655
Medical Information Direct Line: +44 (0)1753 447 690
Medical Information e-mail: Medicalinformationuk@ucb.com
Customer Care direct line: +44 (0) 1773 510123

Summary of Product Characteristics last updated on the eMC: 27/09/2010
SPC Magnesium Sulphate Injection 50% (UCB Pharma Ltd)

When a pharmaceutical company changes an SPC or PIL, a new version is published on the eMC. For each version, we show the dates it was published on the eMC and the reasons for change.

Updated on 27/09/2010 and displayed until Current
Reasons for adding or updating:
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for Use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.6 - Pregnancy and Lactation
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
  • Change to section 4.2 - Posology and method of administration
Date of revision of text on the SPC:   01-Sep-2010
Legal Category:   POM
Black Triangle (CHM):   NO

Free-text change information supplied by the pharmaceutical company



Changes to section 4.2 - Posology and method of administration

Changes to section 4.3 - Contraindications

Changes to section 4.4 – Special warnings

Changes to section 4.5 – Interaction

Changes to section 4.6 – pregnancy and lactation

Changes to section 4.8 – Side effects

Changes to section 4.9 – Overdose

Updated on 15/09/2005 and displayed until 27/09/2010
Reasons for adding or updating:
  • Change to section 7 - Marketing Authorisation Holder
  • Change to section 10 (date of (partial) revision of the text
Updated on 11/06/2003 and displayed until 15/09/2005
Reasons for adding or updating:
  • Correction of spelling/typing errors
Updated on 26/11/2002 and displayed until 11/06/2003
Reasons for adding or updating:
  • Change to section 4.5 - Interactions with other Medicaments and other forms of Interaction
  • Change to section 4.8 - Undesirable Effects
  • Change to section 4.9 - Overdose
Updated on 13/08/2001 and displayed until 26/11/2002
Reasons for adding or updating:
  • New SPC for eMC ie an SPC for an existing product, but one that is new for the eMC

Active Ingredients/Generics

 
   magnesium sulphate